Origin randomizes first patient in diabetic foot ulcer study

Friday, June 2, 2017

Origin, Inc. (formerly Advanced Plasma Therapies, Inc), a Princeton, NJ-based clinical-stage wound care company focused on treatment of Diabetic Foot Ulcers (DFUs) has announced that the first 52 patients have been randomized in the “GENESIS” trial, marking the passing of the halfway enrollment point for the study. The first patient in the study was randomized on March 21, 2017. These patients are being treated in its U.S. dose-ranging Phase IIb “GENESIS” trial. Additionally, all the sites designated for the study have been activated. Origin has developed a proprietary technology to generate and deliver therapeutic quantities of plasma-generated Nitric Oxide (NO) for a wide range of potential human health benefits. The GENESIS trial is designed to demonstrate healing and optimize the treatment regimen for chronic Diabetic Foot Ulcers (DFUs).

[Read More]